Anup Marda
Vermögen: 189 000 $ am 31.05.2026
Vermögen: 189 000 $ am 31.05.2026
Anup Marda is currently Chief Financial & Accounting Officer at Cabaletta Bio, Inc. since 2019.
Formerly, Mr. Marda was Executive Director at US Pharmaceuticals, Inc. from 2012 to 2014 and VP, Head-Global Financial Planning & Analysis at Bristol Myers Squibb Co. from 2018 to 2019.
Education includes an undergraduate degree from Indian Institute of Technology Bombay and an MBA from Krannert School of Management.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CABALETTA BIO, INC. 0,05 % | 02.03.2026 | 50.000 ( 0,05 % ) | 189 000 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CABALETTA BIO, INC. | Finanzdirektor/CFO | 01.01.2019 |
| Unternehmen | Position | Ende |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2019 |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Direktor/Vorstandsmitglied | 01.01.2014 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Health Technology |
Indian Institute of Technology Bombay
Indian Institute of Technology Bombay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Krannert School of Management
Krannert School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which discovers and develops engineered cell therapies for B cell-mediated autoimmune diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen